Parallel Advisors’s Therapix Biosciences Ltd. TRPX Stock Holding History

Parallel Advisors’s Portfolio TRPX Stock Details TRPX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q1	–	Sell	-200	Closed	–	–	2455
2018 Q4	$0	Hold	200	–	–	﹤0.01%	2376
2018 Q3	$1K	Hold	200	–	–	﹤0.01%	2195
2018 Q2	$0	Hold	200	–	–	﹤0.01%	2261
2018 Q1	$1K	Hold	200	–	–	﹤0.01%	2044
2017 Q4	$1K	Hold	200	–	–	﹤0.01%	2040
2017 Q3	$1K	Hold	200	–	–	﹤0.01%	2052
2017 Q2	$1K	Buy	+200	New	+$1.39K	﹤0.01%	2054

Other funds holding TRPX

Hudson Bay Capital Management Stamford, Connecticut $29B AUM 30.2% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

CVI Holdings Wilmington, Delaware $116M AUM 5.68% 1-Year Est. Return

APA

American Portfolios Advisors Holbrook, New York $2.36B AUM 14.59% 1-Year Est. Return

Parallel Advisors's TRPX Position: Q1 2019 in Review

Parallel Advisors sold out of Therapix Biosciences Ltd. (TRPX) in Q1 2019, closing a stake of 200 shares.

Parallel Advisors first reported a position in TRPX in Q2 2017 and held it in 7 quarters. The position peaked at $1K in Q3 2018. 4 funds tracked by Wall St. Rank hold TRPX as of Q1 2019.

Parallel Advisors reported no remaining Therapix Biosciences Ltd. position as of Q1 2019 after selling out during the quarter.
Parallel Advisors sold 200 Therapix Biosciences Ltd. shares in Q1 2019.
Parallel Advisors first reported a position in Therapix Biosciences Ltd. in Q2 2017 and held it in 7 quarters.
Parallel Advisors's Therapix Biosciences Ltd. position peaked at $1K in Q3 2018.
4 funds tracked by Wall St. Rank held Therapix Biosciences Ltd. as of Q1 2019.

Based on Parallel Advisors's 13F filing for Q1 2019, filed 1 May 2019.